Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy …
M Kotaka, S Iwamoto, H Satake, D Sakai… - International Journal of …, 2020 - Springer
Background Chemotherapy in relapsed colorectal cancer patients treated with oxaliplatin as
adjuvant chemotherapy is under debate. REACT study aimed to investigate the efficacy of …
adjuvant chemotherapy is under debate. REACT study aimed to investigate the efficacy of …
FOLFIRI+ bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials
GD Beretta, F Petrelli, S Stinco, M Cabiddu, M Ghilardi… - Medical oncology, 2013 - Springer
Irinotecan and infusional 5-fluorouracil-based chemotherapy (FOLFIRI) plus bevacizumab
(FOLFIRI-B) is one of the most effective treatments of advanced colorectal cancer (CRC) …
(FOLFIRI-B) is one of the most effective treatments of advanced colorectal cancer (CRC) …
Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study
M Suenaga, N Mizunuma, S Matsusaka… - Drug design …, 2015 - Taylor & Francis
Background The effectiveness of reintroducing oxaliplatin in patients with metastatic
colorectal cancer refractory to standard chemotherapy has not been verified. We performed …
colorectal cancer refractory to standard chemotherapy has not been verified. We performed …
Retrospective analysis of the effect of CAPOX and mFOLFOX6 dose intensity on survival in colorectal patients in the adjuvant setting
A Mamo, J Easaw, F Ibnshamsah, A Baig, YS Rho… - Current …, 2016 - mdpi.com
Background: Despite lack of a true comparative study, the folfox (5-fluorouracil–leucovorin–
oxaliplatin) and capox (capecitabine–oxaliplatin) regimens are believed to be similar in their …
oxaliplatin) and capox (capecitabine–oxaliplatin) regimens are believed to be similar in their …
P-76 Phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin/fluoropyrimidine (RAINCLOUD)
N Sugimoto, K Nakata, M Miyo, S Yoshioka… - Annals of …, 2022 - annalsofoncology.org
Background The RAISE study demonstrated the superiority of FOLFIRI plus ramucirumab
(Ram) to FOLFIRI in second-line metastatic colorectal cancer (CRC) patients progressed …
(Ram) to FOLFIRI in second-line metastatic colorectal cancer (CRC) patients progressed …
The meaning of a combination use of bevacizumab in reintroduction of oxaliplatin for metastatic colorectal cancer
K Nishimura, N Nakayama, T Egawa, T Kenmochi… - Annals of …, 2014 - Elsevier
Background: There are some reports that reintroduction of oxaliplatin for metastatic
colorectal cancer was efficacious and feasible. The relationship between response of …
colorectal cancer was efficacious and feasible. The relationship between response of …
[HTML][HTML] Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer …
Y Kagawa, C Wang, Y Piao, L Jin, Y Tanizawa, Z Cai… - Targeted Oncology, 2024 - Springer
Background Oxaliplatin-containing adjuvant regimens (folinic acid, fluorouracil, and
oxaliplatin/capecitabine and oxaliplatin [FOLFOX/CAPOX]) are used after curative resection …
oxaliplatin/capecitabine and oxaliplatin [FOLFOX/CAPOX]) are used after curative resection …
[HTML][HTML] Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
K Ishibashi, T Aoyama, M Kotaka, H Satake… - Cancer Chemotherapy …, 2021 - Springer
Background The aim of this study was to evaluate the efficacy and safety of first-line
chemotherapy with re-introduction of oxaliplatin (OX) more than 6 months after adjuvant …
chemotherapy with re-introduction of oxaliplatin (OX) more than 6 months after adjuvant …
[PDF][PDF] FOLFOX plus cetuximab in first-line therapy of advanced colorectal cancer
R Ehrenberg, N Halama - Annals of Translational Medicine, 2018 - cdn.amegroups.cn
Oxaliplatinum is derivate of platinum, which has been used for colorectal cancer since 1997
in France for first-line therapy of metastatic colorectal cancer. Following the data from the …
in France for first-line therapy of metastatic colorectal cancer. Following the data from the …
Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy
AH de Gramont Lesparre, B Chibaudel… - Journal of Clinical …, 2009 - ascopubs.org
4024 Background: Oxaliplatin combined with fluoropyrimidines is standard adjuvant therapy
in stage III colon cancer and first-line therapy in stage IV colorectal cancer. Oxaliplatin can …
in stage III colon cancer and first-line therapy in stage IV colorectal cancer. Oxaliplatin can …